Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme a reductase: The concept of cholesterol buffering capacity (44508)

Experimental Biology and Medicine

Volumn 224, Issue 1, 2000, Pages 8-19

  Ness, Gene C ^a   Chambers, Christopher M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN; GLUCAGON; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; THYROID HORMONE;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CIRCADIAN RHYTHM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; HORMONAL REGULATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ANIMALS; CHOLESTEROL; CIRCADIAN RHYTHM; FEEDBACK; HOMEOSTASIS; HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIVER; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0034093374     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.2000.22359.x     Document Type: Article

References (13)

1. Singer II, Kawaka DW, Kazazis DM, Alberts AW, Chen JS, Huff JW, Ness GC. Hydroxymethylglutaryl coenzyme A reductase containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci U S A 81:5556-5560, 1984.
2. Bucher NLR, Overath P, Lynen F. 3-Hydroxy-3-methylglutaryl coenzyme A reductase, cleavage, and condensing enzymes in relation to cholesterol formation in rat liver. Biochim Biophys Acta 40:491-501, 1960.
3. Bloch K. Summing up. Ann Rev Biochem 56:1-19, 1987.
4. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47, 1986.
5. Bjorkhem I. Mechanism of bile acid biosynthesis in mammalian liver. In: Danielsson H, Sjovall J, Eds. Sterols and Bile Acids. Amsterdam: Elsevier, pp231-278, 1985.
6. Porter JA, Young KE, Beachy PA. Cholesterol modification of hedgehog signaling proteins in animal development. Science 274:255-259, 1995.
7. Tint GS, Irons M, Elias MR, Batta AK, Frieden R, Chen TS, Salen G. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 330:107-113, 1994.
8. Irons M, Elias MR, Tint GS, Salen G, Frieden R, Buie TM, Ampola M. Abnormal cholesterol metabolism in the Smith-Lemli-Opitz syndrome-TypeII: Report of clinical and biochemical findings in four patients and treatment in one patient. Am J Med Genet 50:347-352, 1994.
9. Grundy SM. Cholesterol and coronary heart disease: A new era. JAMA 256:2849-2858, 1986.
10. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343:425-430, 1990.
11. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper HW. Expanded clinical evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151:43-49, 1991.
12. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian coronary atherosclerosis intervention trial. Circulation 89:959-968, 1994.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study. Lancet 344:1383-1389, 1994.